CAMBRIDGE, Mass.--(BUSINESS WIRE)--Epizyme, Inc. (NASDAQ:EPZM), a clinical stage biopharmaceutical company creating novel epigenetic therapies for people with cancer, today announced that the Company will participate in four investor conferences in February:
- 2016 Canaccord Genuity Rare Disease, BioPharma One-On-One Day, Tuesday, February 2 at the Omni Berkshire Place in New York.
- LEERINK Partners 5th Annual Global Healthcare Conference, fireside chat on Wednesday, February 10 from 11:05 AM to 11:25 AM at the Waldorf Astoria in New York. A replay of the webcast can be accessed at the investor section of http://www.epizyme.com.
- SunTrust Robinson Humphrey's 2016 Orphan Drug Day, Tuesday, February 23 at the JW Marriott Essex House in New York.
- RBC Healthcare Conference, fireside chat on Wednesday, February 24 from 8:00 AM to 8:30 AM in New York. A replay of the webcast can be accessed at the investor section of http://www.epizyme.com.
About Epizyme, Inc.
Epizyme, Inc. is a clinical-stage biopharmaceutical company creating novel epigenetic therapeutics for cancer patients. Epizyme has built a proprietary product platform that the Company uses to create small molecule inhibitors of chromatin modifying proteins (CMPs), such as histone methyltransferases or HMTs. CMPs are part of the system of gene regulation, referred to as epigenetics, that controls gene expression. Genetic alterations can result in changes to the activity of CMPs, making them oncogenic (cancer-causing). By focusing on the genetic drivers of cancers, Epizyme's targeted science seeks to match the right medicines with the right patients.
For more information, visit www.epizyme.com and connect with us on Twitter at @EpizymeRx.